

1 **Complex Patient Perspectives on Evolving Diverticulitis Treatment**

2 3 **Patient Perspectives on Diverticulitis**

4
5 Annie Altman-Merino BS¹, Kemberlee Bonnet, MA², David Schlundt PhD², Jessie Wrenn, MD,
6 PhD^{3,4}, Wesley H. Self, MD, MPH⁵, Elisa J. Gordon PhD, MPH⁶, Alexander T. Hawkins MD,
7 MPH⁷

8
9 ¹School of Medicine, Vanderbilt University, Nashville, TN

10 ²Department of Psychology, Vanderbilt University, Nashville, TN

11 ³Vanderbilt University Medical Center, Department of Emergency Medicine, Nashville, TN

12 ⁴Vanderbilt University Medical Center Department of Biomedical Informatics, Nashville, TN

13 ⁵ Vanderbilt University Medical Center, Vanderbilt Institute for Clinical and Translational
14 Research and Department of Emergency Medicine, Nashville, TN

15 ⁶Vanderbilt University Medical Center, Department of Surgery, and Center for Biomedical
16 Ethics and Society, Nashville, TN.

17 ⁷Vanderbilt University Medical Center, Division of General Surgery, Section of Colon & Rectal
18 Surgery, Nashville, TN.

19
20 Address for correspondence:

21 Alexander T Hawkins, MD, MPH

22 Section of Colon & Rectal Surgery

23 Vanderbilt University

24 1161 21st Ave South

25 Room D5248 MCN

26 Nashville, TN 37232

27 Office: 615.343.4612

28 Fax: 615.343.4615

29 Email: alex.hawkins at vumc.org

30
31 Email correspondence for all authors:

32 Anne.e.altman-merino@vanderbilt.edu; Kemberlee.bonnet@vanderbilt.edu;

33 David.schlundt@vanderbilt.edu; Jesse.wrenn.1@vumc.org; Welsey.self@vumc.org;

34 Elisa.gordon@vumc.org

35
36 Conflicts of Interest: None

37
38 Funding: Dr Hawkins' work on this manuscript was supported by the National Institute of
39 Diabetes and Digestive and Kidney Disease of the National Institutes of Health under award
40 number K23DK118192. The Vanderbilt Institute for Clinical and Translational Research
41 (VICTR) is funded by the National Center for Advancing Translational Sciences (NCATS)
42 Clinical Translational Science Award (CTSA) Program, Award Number 5UL1TR002243-03
43 (Voucher V0000039202). The content is solely the responsibility of the authors and does not
44 necessarily represent the official views of the National Institutes of Health.

45
46 Text word count: 29921/3000 words

47 Abstract word count: 299/300

48

49 Author contribution:

50 AAM designed and executed all study procedures including manuscript drafting and editing. KB

51 assisted interview guide design, qualitative training of primary author, and manuscript writing.

52 DS supported qualitative analysis including writing of the corresponding manuscript section. JW

53 and WHS assisted with interviewee identification through the emergency department and

54 contributed to writing and editing. EG supported qualitative analysis and contributed to writing

55 and editing. ATH oversaw all study procedures and contributed to writing and editing. All

56 authors reviewed the final manuscript.

57

58 Category: Benign colorectal disease

59

60 **Abstract**

61 Background: Despite evidence that antibiotics may not be necessary to treat acute uncomplicated
62 diverticulitis, they remain the mainstay of treatment in the United States. A randomized
63 controlled trial evaluating antibiotic effectiveness could accelerate implementation of an
64 antibiotic-free treatment strategy, but patients may be unwilling to participate.

65 Objective: This study aims to assess patients' attitudes regarding participation in a randomized
66 trial of antibiotics versus placebo for acute diverticulitis, including willingness to participate.

67 Design: This is a mixed-methods study with qualitative and descriptive methods.

68 Settings: Interviews were conducted in a quaternary care emergency department and surveys
69 were administered virtually through a web-based portal.

70 Patients: Patients with either current or previous acute uncomplicated diverticulitis participated.

71 Interventions: Patients underwent semi-structured interviews or completed a web-based survey.

72 Main Outcome measures: Rates of willingness to participate in a randomized controlled trial was
73 measured. Salient factors related to healthcare decision-making were also identified and
74 analyzed.

75 Results: Thirteen patients completed an interview. Reasons to participate included a desire to
76 help others or contribute to scientific knowledge. Doubts about the efficacy of observation as a
77 treatment method were the main barrier to participation. In a survey of 218 subjects, 62% of
78 respondents reported willingness to participate in a randomized clinical trial. "What my doctor
79 thinks," followed by "What I've experienced in the past" were the most important decision-
80 making factors.

81

82 Limitations: There is possible selection bias inherent to using a study to evaluate willingness to
83 participate in a study. Also, the population sampled was disproportionately White compared to
84 the population affected by diverticulitis.

85

86 Conclusions: Patients with acute uncomplicated diverticulitis maintain complex and varying
87 perceptions of the use of antibiotics. Most surveyed patients would be willing to participate in a
88 trial of antibiotics versus placebo. Our findings support a trial's feasibility and facilitate an
89 informed approach to recruitment and consent.

90

91 Key Words: diverticulitis, diverticular disease, patient perspectives, qualitative analysis,
92 antibiotic stewardship

93

94 **Introduction:**

95 Diverticular disease is one of the most prevalent conditions in the United States, and its
96 incidence is increasing. Acute diverticulitis is a leading cause of emergency department (ED)
97 visits, accounting for over 360,000 visits per year¹. Despite evidence that antibiotics are not
98 necessary to treat acute uncomplicated diverticulitis (AUD)²⁻⁴ and models of diverticulitis
99 pathophysiology suggesting an inflammatory process rather than an infectious one^{5,6}, antibiotics
100 remain the mainstay of treatment in the US.

101 Unnecessary use of antibiotics is harmful. Antibiotic misuse exacerbates antibiotic
102 resistance, accounting for more dangerous infections and difficult-to-eradicate pathogens. In the
103 US, over 2.8 million antibiotic-resistant infections develop per year, resulting in over 35,000
104 associated deaths⁷. Overuse of antibiotics leads to longer hospital stays, more readmissions, and
105 ultimately higher mortality rates due to infectious disease⁸. Antimicrobial resistance due to
106 overuse carries a high economic burden of \$55 billion per year in the US⁷. Management of
107 uncomplicated diverticulitis without antibiotics represents an opportunity to educate prescribers
108 and reduce antibiotic prescriptions for one of the leading causes of ED visits in the US.

109 Despite this, antibiotics remain the standard treatment in the US. Three randomized
110 controlled trials in Europe have demonstrated non-inferiority of symptomatic and supportive care
111 without antibiotics compared to treatment with antibiotics for the outcomes of perforation and
112 abscess formation, median hospital stay, and diverticulitis recurrence²⁻⁴. Guidelines from the
113 American Gastroenterological Association, American Society of Colon and Rectal Surgeons, and
114 American College of Physicians state that uncomplicated cases can be treated without
115 antibiotics⁹⁻¹². The reasons for continued antibiotic use are multifactorial, including lack of
116 physician awareness of updated literature and guidelines, physician fear of medicolegal

117 consequences of “observation,” and patient expectation of treatment with antibiotics¹³. However,
118 the threat of antibiotic resistance is genuine, and continued inappropriate use of antibiotics is
119 antithetical to a rigorous effort to curtail resistance.

120 A North American randomized controlled trial of antibiotics versus no antibiotics for
121 AUD that demonstrated non-inferiority of an antibiotic-free approach would likely help decrease
122 superfluous antimicrobial use for uncomplicated diverticulitis¹³. This study aims to assess
123 patients’ perceptions and attitudes regarding participation in a randomized controlled trial of
124 antibiotics versus no antibiotics for AUD and evaluate willingness to participate in such a trial.

125

126 **Materials and Methods:**

127 This mixed-methods study assessed patient perspectives through focused interviews
128 followed by a survey of a separate, larger cohort to quantify themes that emerged from the
129 interviews. Vanderbilt University Medical Center Institutional Review Board approved this
130 study with allowance of verbal consent for the focused interviews (IRB #2210530) and a waiver
131 of informed consent for surveys (IRB #221611).

132

133 Focused Interviews

134 Semi-structured interviews were conducted both in-person in the Vanderbilt University
135 (VUMC) ED and over the phone. Individuals eligible to participate in in-person interviews
136 included adult (age 18-90 years), English-speaking patients presenting to the VUMC ED with
137 AUD and adequate cognitive capacity to participate. Exclusion criteria for this group included
138 complicated diverticulitis such as bleeding, abscess, or perforation; asymptomatic diverticulitis
139 found incidentally on CT scan; history of colon or rectal cancer, Crohn’s disease, or ulcerative

140 colitis; end-stage renal disease; or previous colectomy. Individuals eligible to participate in
141 phone interviews included adult English-speaking patients with a history of AUD treated at
142 VUMC. Interviews were conducted from October 2022 to December 2022. Once the study team
143 recognized that no novel themes emerged during interviews, it was determined that thematic
144 saturation was reached, and the survey phase concluded¹⁴.

145 The interview guide was created with support from the VUMC Qualitative Research
146 Core¹⁵. It was designed to allow patients to reflect on their expectations, experiences and
147 opinions about diverticulitis using four open-ended questions followed by four focused questions
148 to obtain thoughts about side effects of antibiotics, antibiotic resistance, and treatment guidelines
149 (Full interview guide Supplemental Material 1).

150 Subjects were identified using natural language processing of radiologists' interpretations
151 of computed tomography (CT) scans to identify Unified Medical Language System concepts
152 representing diverticulitis. Study personnel were sent an email alert within minutes of radiology
153 interpretation and reviewed the CT scan, radiology interpretation, and patient chart to ensure
154 eligibility. The interviewer (AAM), a female medical student who underwent qualitative
155 interview training with the Qualitative Research Core, approached eligible participants and
156 obtained verbal consent for participation. The interviewer had no prior relationship to patients
157 and disclosed that she is a medical student with interest in the research topic. Interviewees were
158 not compensated. Interviews were recorded using a Sony ICD-PX370 digital voice recorder.
159 Phone interview participants were identified through an electronic medical record query of
160 patients seen in the VUMC Colon and Rectal Surgery Clinic. The interviewer called participants
161 and obtained verbal consent for participation.

162

163 Qualitative Analysis

164 Audio recordings of interviews were transcribed using an online transcription service
165 (<https://rev.com>) and transcripts were verified manually and not shared with participants. Coding
166 and thematic analysis were conducted by AAM. Interview content was analyzed using open
167 coding and thematic analysis. According to the grounded theory approach, theories were derived
168 from raw data by generating and applying codes¹⁶. The first five transcripts were reviewed, and
169 each line of text was ascribed one or more codes which were derived inductively from the data.
170 After review of the first five transcripts, codes were distilled into a codebook which was
171 referenced to code the remaining transcripts. Thematic analysis was conducted through four
172 steps of qualitative analysis identified by Green et al - immersion in the data, coding, creating
173 categories, and identification of themes¹⁷. Qualitative data collection and analysis were
174 performed in accordance with the Standards for Reporting Qualitative Research¹⁸.

175

176 Survey Methodology

177 Qualitative analysis of interview data informed the development of a web-based survey to
178 quantify attitudes and beliefs of a separate, larger cohort. Individuals eligible to participate in
179 surveys included patients with a history of diverticulitis. Exclusion criteria were a history of
180 colon and rectal cancer, Crohn's disease or ulcerative colitis, end-stage renal disease, or previous
181 colectomy.

182 Using the coded transcripts, potential survey items reflecting patient opinions about
183 antibiotics and treatment of AUD were written. They were organized into an online survey with
184 three sections, each with five items that participants were asked to rank from least important to
185 most important. The survey was reviewed and revised by the research team and beta tested by

186 both physicians and patients. It was distributed as an online survey using REDCap¹⁹. Additional
187 free text items asked participants to describe their reasons for being willing or unwilling to
188 participate in a randomized clinical trial. (Supplemental Material 2).

189 Survey participants were identified using social media, VUMC’s electronic health record
190 (EHR), and ResearchMatch, a national health volunteer registry supported by the US National
191 Institutes of Health as part of the Clinical Translational Science Award program. An IRB-
192 approved recruitment message was posted on diverticulitis-related social media pages and sent to
193 eligible ResearchMatch volunteers (Supplemental Materials 3). Eligible participants identified
194 via ICD-10 codes through the EHR were contacted with an IRB-approved message through My
195 Health at Vanderbilt, VUMC’s patient health portal. Participants were given the option to enter a
196 raffle to win a \$100 gift certificate upon completion of the survey. Participants were screened for
197 eligibility through a REDCap survey and given access to the study survey if they met eligibility.

198

199 Survey Data Analysis

200 Descriptive statistics were performed to examine frequencies, means, and standard
201 deviations in survey data. Ranked factors were viewed by number of times ranked “most
202 important” and number of times ranked “least important.” Qualitative analysis was applied to
203 participants’ explanations of willingness or unwillingness to participate with an open coding and
204 thematic analysis approach similar to the methods described in the focused interview section.

205

206 **Results**

207 Participant Characteristics

208 Thirteen patients completed an interview: nine in the ED with an episode of AUD and
209 four over the phone without a current episode (100% participation for in-person interviews, 67%
210 for phone interviews). All were interviewed alone and only once. Most participants were female
211 (62%, n=8/13) and non-Hispanic White (85%, n=11/13). Detailed patient characteristics are
212 presented in Table 1. Participants had a mean age of 62 years. Mean interview duration was 16
213 minutes (SD 6 minutes).

214

215 Themes

216 Two salient themes that emerged were sources of information used in decision making
217 and factors contributing to reluctance or desire to participate in a trial. Information sources
218 guiding the decision-making process included personal experiences along with provider
219 recommendations. Patients reporting reluctance to participate in a trial commonly expressed
220 doubts about the efficacy of observation as a treatment strategy. Themes regarding willingness to
221 participate were desire to avoid antibiotics in the future, to help others, and to contribute to
222 public knowledge. Figure 1 demonstrates a conceptual model of factors contributing to
223 reluctance or desire to participate. Table 2 includes quotations illustrating each of these themes.

224

225 Sub-Theme 1: Personal History and Experiences

226 Participants referenced personal experiences of disease episodes when considering
227 participation in a trial and chronicled a recurring sequence of events: diagnosis of diverticulitis,
228 antibiotic administration, and subsequent symptom resolution. Recognizing and reflecting on the
229 pattern of symptom resolution after antibiotics influenced how participants considered
230 participation in a trial where they may not receive antibiotics.

231

232 *So to be honest, it seems that from my experience, and I know it's anecdotal, it*

233 *seems [to] suggest there was a physiological change from the medication.*

234 *(Participant 2)*

235

236 Participant 2 reflected on his past experiences, and by the end of the discussion, had

237 drawn upon them to reach a decision:

238

239 *Well, talking it out, it's kind of helped me process and see that from a very first*

240 *episode, it seems like the amoxicillin was effective... So actually, just talking to*

241 *you, I started to lean more towards staying with amoxicillin. (Participant 2)*

242

243 Patients' perceptions of antibiotic efficacy in the past, whether perceived as high or low efficacy,

244 informed decisions about participation in a trial. This individual perceived that antibiotics were

245 effective during previous episodes, which precipitated reluctance to participate in a trial. Given

246 the recurring and episodic nature of diverticular disease, personal experience is particularly

247 salient to decisions about disease management.

248

249 Sub-Theme 2: Influence of Providers on Participant Perceptions

250 Participants considered providers' recommendations about whether antibiotics would be

251 beneficial as central to their perceptions of diverticulitis treatment. Some participants identified

252 their individual primary care provider or the ED provider as trusted sources of guidance about

253 treatment options.

254

255 *I think I would need to talk to my doctor, my family doctor. I think that would be*
256 *my best bet. (Participant A)*

257

258 Others invoked the authority of providers as a collective medical community who have accepted
259 antibiotics as the standard treatment.

260

261 *You just trust the science or whatever ... it doesn't matter which doctor,*
262 *everybody prescribes the antibiotic regardless So I've never questioned it*
263 *because that's what they say it takes. (Participant 5)*

264

265 Sub-Theme 3: Observation Hesitancy

266 Most participants who were unwilling to participate in a trial doubted the efficacy of
267 observation as a treatment strategy, believing that antibiotics are necessary for recovery. These
268 participants tended to view the omission of antibiotics as the omission of treatment.

269

270 *At least when I have it, I mean, I can't imagine if there was no treatment, because*
271 *I've had to wait before to get treatment and it didn't get any better. (Participant 6)*

272

273 The interviewer informed participants that the placebo arm would receive treatment in the
274 form of supportive care, pain control, and close observation. However, some participants
275 interpreted the lack of antibiotics as “no treatment.”

276

277 *So if I'm getting the sugar pill then I'm in the control group, does that mean I'm*
278 *not getting any treatment at all? (Participant B)*

279

280 Sub-Theme 4: Desire to Avoid Antibiotics in the Future

281 Aversion towards antibiotics contributed to both reluctance and desire to participate.

282 Some patients feared placement in the antibiotic study group and others saw participation in the
283 study as a means of avoiding antibiotics in the future.

284

285 *But I never take an antibiotic unless I have to. I just am afraid it would - you take*
286 *too many and it won't work. (Participant C)*

287

288 Concern about taking any medication and aversion to unnecessary medical treatment in general
289 were commonly shared sentiments.

290

291 *Well, I think that people get over-medicated sometimes, I do. (Participant 4)*

292

293 Sub-Theme 5: Helping Others and Advancing Public Knowledge

294 The public impact of study participation, including advancing public knowledge and
295 helping others, were primary drivers of patients' willingness to participate.

296

297 *I struggle with this for 10 years and any advancement in the treatment, I'd be glad*
298 *to be part of that. Yeah, it would help a lot of people, I would think. (Participant*

299 *2)*

300

301 Survey Quantitative Results

302 Two hundred and eighteen participants completed the survey. Participation rate by
303 method is demonstrated in Figure 2. Mean participant age was 57.9 years (SD 13.3 years), and
304 most were female (61.9%), and non-Hispanic White (69.7%). Detailed patient characteristics are
305 presented in Table 3.

306 One Hundred and thirty-five respondents (62%) reported willingness to participate in a
307 trial of antibiotics versus placebo during an episode of AUD. Figure 3 illustrates the number of
308 times each factor was ranked most important. The two leading reasons to participate included
309 “Helping make guidelines for treatment better” (48%) and “Avoiding antibiotics” (22%).

310 When prompted to rank the importance of various factors used to make healthcare
311 decisions, the leading factors were “What my doctor thinks,” (56%) and “What I’ve experienced
312 in the past” (36%). Only 5% reported “What the doctor seeing me in the Emergency Department
313 thinks” as most important. “Needing an ostomy bag” was the most feared outcome of
314 diverticulitis (55%).

315

316 Qualitative Results of Surveys

317 Among 83 who reported unwillingness to participate, 67 explained their response. These
318 explanations largely fall into two categories: fear of an antibiotic-free treatment and aversion to
319 antibiotics themselves.

320

321 *I have had diverticulitis three times and each time it was cleared up with*
322 *antibiotics. The thought of getting a placebo scares me. (Male in their 60s)*

323

324 Fear of not receiving antibiotics contrasts with preference for a non-antibiotic strategy.

325

326 *Don't trust antibiotics. Makes it worse. Longer to heal. (Male in their 60s)*

327

328 Those who were willing to participate specified a desire to help others, contribute to
329 diverticulitis-related research, or understand the disease themselves.

330

331 *I like to help and would like a better understanding of diverticulitis. (Female in their 40s)*

332

333 **Discussion and Conclusions**

334 . Considering that patient hesitancy to participate in a trial of antibiotics versus placebo
335 has been a major barrier to its execution, understanding patients' opinions is essential to
336 conducting a trial and ultimately implementing a change in the standard treatment of
337 diverticulitis. Both qualitative literature and literature regarding patient perspectives are
338 increasingly recognized as important for informing treatment strategies and understanding trial
339 recruitment^{14, 20-22}. This mixed-methods study assessed patients' perceptions of diverticulitis
340 treatment options through semi-structured interviews with patients in addition to a survey of a
341 larger cohort, and found that most patients with a history of diverticulitis report willingness to
342 participate in a trial of antibiotics versus placebo for AUD. It also identified factors that patients
343 consider when making decisions related to their healthcare, with their doctor's recommendation
344 being the most important.

345 Over 60% of survey respondents reported willingness to participate in a trial of
346 antibiotics versus placebo for AUD. This enthusiasm for trial participation would support robust
347 enrollment in an actual trial and scientific integrity. Our findings support the feasibility of such a
348 trial and can be applied during its planning and execution to facilitate patient-centeredness in
349 methods and analysis. This number is especially encouraging when compared to participation
350 rates in similar US surgical trials that have recruited from the ED. For example, the CODA trial,
351 comparing antibiotics with appendectomy for appendicitis, had a 31% enrollment rate among
352 eligible patients²³.

353 Confidence in providers was evident in conversations with patients and survey responses.
354 ED provider opinions carried weight particularly in interviews, where these providers were the
355 first to communicate diagnoses and present treatment options. Interviewees also expressed
356 confidence in doctors and the medical community to make the best decision for them. These
357 findings highlight the potential for providers to affect patient perspectives on the use of an
358 antibiotic-free strategy.

359 A key strength of this study is that interviews simulated enrollment in an RCT: most
360 patients were recruited in the ED at the time of diagnosis, before either discharge or hospital
361 admission. This recruitment approach provided a unique view into patient perceptions of
362 treatment options at the time that they would be enrolled, and therefore reflected authentic
363 concerns, doubts, and questions that typically arise in that context.

364 Our study has limitations. There is the possibility of selection bias, which is inherent to
365 conducting a study to evaluate willingness to participate in a study. However, all individuals
366 approached in-person in the ED agreed to participate in an interview, indicating that the
367 population was not skewed towards those who are more inclined to participate. The population

368 sampled was disproportionately White compared to the population affected by diverticulitis,
369 meaning that the perspectives of some voices underrepresented in biomedical research are left
370 out. Another limitation was that survey respondents did not have the opportunity to engage in
371 dynamic discussion with the research team. Some participants misunderstood the explanation of
372 the trial and indicated unwillingness to undergo randomization because they were not currently
373 experiencing symptoms. Consequently, participants' willingness may have been underestimated.

374 In conclusion, the most important factors guiding patients' decision making about
375 diverticulitis treatment include recommendations by trusted providers and perceptions of
376 observation as ineffective treatment. These factors may be modulated over time as providers
377 accept an antibiotic-free approach and affirm its legitimacy to patients. A US-based randomized
378 controlled trial of antibiotics versus placebo for acute uncomplicated diverticulitis is feasible in
379 terms of patient recruitment, and even anticipated by patients.

380

381 **Acknowledgements**

382

383 We thank Dario Giuse, Dr. Ing, MS, FACMI, for his contribution to the study.

384

385 **References**

- 386 1. Bollom A, Austrie J, Hirsch W, et al. Emergency department burden of diverticulitis in
387 the USA, 2006-2013. *Dig Dis Sci*. 2017;62:2694–2703.
- 388 2. Chabok A, Pählman L, Hjern F, Haapaniemi S, Smedh K; AVOD Study Group.
389 Randomized clinical trial of antibiotics in acute uncomplicated diverticulitis. *Br J Surg*.
390 2012;99(4):532-539. doi:10.1002/bjs.8688

- 391 3. Daniels L, Ünlü Ç, de Korte N, et al. Randomized clinical trial of observational versus
392 antibiotic treatment for a first episode of CT-proven uncomplicated acute
393 diverticulitis. *Br J Surg*. 2017;104(1):52-61. doi:10.1002/bjs.10309
- 394 4. Mora-López L, Ruiz-Edo N, Estrada-Ferrer O, et al. Efficacy and Safety of Nonantibiotic
395 Outpatient Treatment in Mild Acute Diverticulitis (DINAMO-study): A Multicentre,
396 Randomised, Open-label, Noninferiority Trial. *Ann Surg*. 2021;274(5):e435-e442.
397 doi:10.1097/SLA.0000000000005031
- 398 5. Piscopo N, Ellul P. Diverticular Disease: A Review on Pathophysiology and Recent
399 Evidence. *Ulster Med J*. 2020;89(2):83-88.
- 400 6. Zullo A. Medical hypothesis: speculating on the pathogenesis of acute diverticulitis. *Ann*
401 *Gastroenterol*. 2018;31(6):747-749.
- 402 7. Centers for Disease Control and Prevention. Antibiotic Resistance Threats in the United
403 States. [https://www.cdc.gov/drugresistance/pdf/threats-report/2019-ar-threats-report-](https://www.cdc.gov/drugresistance/pdf/threats-report/2019-ar-threats-report-508.pdf)
404 [508.pdf](https://www.cdc.gov/drugresistance/pdf/threats-report/2019-ar-threats-report-508.pdf). 2019.
- 405 8. Dadgostar P. Antimicrobial Resistance: Implications and Costs. *Infect Drug Resist*.
406 2019;12:3903-3910. Published 2019 Dec 20. doi:10.2147/IDR.S234610Dadgostar P.
407 Antimicrobial Resistance: Implications and Costs. *Infect Drug Resist*. 2019;12:3903-
408 3910. Published 2019 Dec 20. doi:10.2147/IDR.S234610
- 409 9. Peery AF, Shaukat A, Strate LL. AGA Clinical Practice Update on Medical Management
410 of Colonic Diverticulitis: Expert Review. *Gastroenterology*. 2021;160(3):906-911.e1.
411 doi:10.1053/j.gastro.2020.09.059
- 412 10. Stollman N, Smalley W, Hirano I; AGA Institute Clinical Guidelines Committee.
413 American Gastroenterological Association Institute Guideline on the Management of

- 414 Acute Diverticulitis. *Gastroenterology*. 2015;149(7):1944-1949.
415 doi:10.1053/j.gastro.2015.10.003
- 416 11. Hall J, Hardiman K, Lee S, et al. The American Society of Colon and Rectal Surgeons
417 Clinical Practice Guidelines for the Treatment of Left-Sided Colonic Diverticulitis. *Dis*
418 *Colon Rectum*. 2020;63(6):728-747. doi:10.1097/DCR.0000000000001679
- 419 12. Qaseem A, Etzeandia-Ikobaltzeta I, Lin JS, et al. Diagnosis and Management of Acute
420 Left-Sided Colonic Diverticulitis: A Clinical Guideline From the American College of
421 Physicians. *Ann Intern Med*. 2022;175(3):399-415. doi:10.7326/M21-2710
- 422 13. Garfinkle R, Sabboobeh S, Demian M, Barkun A, Boutros M; Management of
423 Uncomplicated Diverticulitis (MUD) Collaborative. Patient and Physician Preferences
424 for Antibiotics in Acute Uncomplicated Diverticulitis: A Delphi Consensus Process to
425 Generate Noninferiority Margins. *Dis Colon Rectum*. 2021;64(1):119-127.
426 doi:10.1097/DCR.0000000000001815
- 427 14. Saunders B, Sim J, Kingstone T, et al. Saturation in qualitative research: exploring its
428 conceptualization and operationalization. *Qual Quant*. 2018;52(4):1893-1907.
429 doi:10.1007/s11135-017-0574-8
- 430 15. Vanderbilt University Medical Center (2023). *Vanderbilt University Qualitative*
431 *Research Core*. Vanderbilt Institute for Medicine and Public Health. Retrieved May 3,
432 2023, from <https://www.vumc.org/hsr/qualitative-research-core>
- 433 16. Chun Tie Y, Birks M, Francis K. Grounded theory research: A design framework for
434 novice researchers. *SAGE Open Med*. 2019;7:2050312118822927. Published 2019 Jan 2.
435 doi:10.1177/2050312118822927

- 436 17. Green J, Willis K, Hughes E, et al. Generating best evidence from qualitative research:
437 the role of data analysis. *Aust N Z J Public Health*. 2007;31(6):545-550.
438 doi:10.1111/j.1753-6405.2007.00141.x
- 439 18. O'Brien BC, Harris IB, Beckman TJ, Reed DA, Cook DA. Standards for reporting
440 qualitative research: a synthesis of recommendations. *Acad Med*. 2014;89(9):1245-1251.
441 doi:10.1097/ACM.0000000000000388
- 442 19. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic
443 data capture (REDCap)--a metadata-driven methodology and workflow process for
444 providing translational research informatics support. *J Biomed Inform*. 2009;42(2):377-
445 381. doi:10.1016/j.jbi.2008.08.010
- 446 20. Ndjaboue R, Chipenda Dansokho S, Boudreault B, et al. Patients' perspectives on how to
447 improve diabetes care and self-management: qualitative study. *BMJ Open*.
448 2020;10(4):e032762. Published 2020 Apr 29. doi:10.1136/bmjopen-2019-032762
- 449 21. Moorcraft SY, Marriott C, Peckitt C, et al. Patients' willingness to participate in clinical
450 trials and their views on aspects of cancer research: results of a prospective patient
451 survey. *Trials*. 2016;17:17. Published 2016 Jan 9. doi:10.1186/s13063-015-1105-3
- 452 22. Ferrell B, Williams AC, Borneman T, Chung V, Smith TJ. Clinical Trials: Understanding
453 Patient Perspectives and Beliefs About Treatment. *Clin J Oncol Nurs*. 2019;23(6):592-
454 598. doi:10.1188/19.CJON.592-598
- 455 23. CODA Collaborative, Flum DR, Davidson GH, et al. A Randomized Trial Comparing
456 Antibiotics with Appendectomy for Appendicitis. *N Engl J Med*. 2020;383(20):1907-
457 1919. doi:10.1056/NEJMoa2014320

458

459 **Figure Legends**

460 Table 1. Characteristics of interview participants.

461 Table 2. Summary of themes and representative quotes.

462 Table 3. Characteristics of survey participants.

463 Figure 1. Conceptual model of factors contributing to reluctance or desire to participate.

464 Figure 2. Survey participation rate by recruitment method.


465 Figure 3. Survey factors represented by times ranked “Most Important,” including A, reasons to
466 participate in a randomized controlled trial of antibiotics versus placebo, B, factors used to make
467 healthcare decisions, and C, feared outcomes of diverticulitis.


Interview Participant Characteristics		
Variable		N (%)
Age, mean, (SD)		62.4 (13.0)
Age by Category		
	18-29 years	0 (0)
	30-49 years	3 (23)
	50-64 years	5 (38)
	≥ 65 years	5 (38)
Sex	Female	8 (62)
	Male	5 (38)
Ethnicity	Hispanic or Latino	0 (0)
	Not Hispanic or Latino	13 (100)
Race/Ethnicity	White, Non-Hispanic	11 (85)
	Black or African American	2 (15)
	Asian	0 (0)
	More than one race	0 (0)
Interview Type	In-Person	9 (69)
	Phone	4 (31)
Number of Diverticulitis Episodes	1st episode	5 (38)
	2 - 5	4 (30)
	6 - 10	2 (15)
	11 - 20	1 (8)
	> 20	1 (8)

Theme	Subtheme	Quotations
Personal History and Experiences	Antibiotic Effectiveness	With my first episode, I didn't know what it was, and so I had delayed treatment, so it got extremely infected at a bad abscess... And then after that, then I realized that immediate treatment was important. So every time I'd have the symptoms, I would go to the ER as soon as possible...from my experience, catching it as early as possible was critical because delayed treatment clearly, in my experience, made it much worse. (Participant 5)
	Antibiotic Inefficacy	I've had so many episodes and found that [antibiotics] really didn't help. And now my interpretation was that I didn't instantly get better. I got only got better with time as the inflammation settled down. That's my interpretation. (Participant D)
Provider Opinion	Known provider	I would rely on my doctor if he told me that this is a situation that can be alleviated through pain management and some other medication or no medication. (Participant 7)
	ED provider	I guess I'm just kind of going on what [the ED doctor] said. If his recommendation was the antibiotic, then I think that would be what I would do. If he said, you can take this or not, and it's going to be the same outcome, I don't know. That might change it if he had said something else. (Participant 6)
	General medical community	I mean, I take it when they tell me I need it and I go blindly...see, as we all do, maybe. (Participant 9)
Observation Hesitancy		That would be my number one concern is what if it doesn't work? How long do I have to stay in pain before we can go back to what works? (Participant 5)
Avoiding antibiotics in the future	Antibiotic hesitancy	I don't ever like to take an antibiotic unless I have to. Okay. Now I'm taking one drug right now that I... I have to take, but I take it, and it has had side effects. So as long as I've been on it, and it's called oh gosh... And when I first got on it, I had such severe diarrhea, I couldn't leave the house about three or four hours. (Participant C)
	Healthcare hesitancy	I used to be involved in the fitness industry and there was a lot of people that were my associates that were very into nutrition, and they believed in healing yourself through healthy eating and exercise and didn't like medication.... So I think we overdo it and I think we damage our immune systems. (Participant 1)
Public Impact	Helping Others	I think research is research and as we progress, medicine progresses. So I think whatever needs to be done to, for the betterment of everyone, is what needs to be done. (Participant 8)
	Advancing public knowledge	I mean, on one hand I want to participate in anything it's going to help advance treatment. (Participant 2)


Survey Participant Characteristics

Variable		N (%)
Age, mean, (SD)		57.9 (13.3)
Age by Category	18-29 years	3 (1.4)
	30-49 years	55 (25.2)
	50-64 years	68 (31.2)
	≥ 65 years	81 (37.2)
Sex	Female	135 (61.9)
	Male	77 (35.3)
	Other/Prefer not to say	2 (0.9)
	Not reported	4 (1.8)
Ethnicity	Hispanic or Latino	12 (5.5)
	Not Hispanic or Latino	191 (87.6)
	Unknown	3 (1.4)
	Not reported	12 (5.5)
Race/Ethnicity	White, Non-Hispanic	152 (69.7)
	Black or African American	9 (4.1)
	Asian	1 (0.5)
	More than one race	4 (1.8)
	Not reported	31 (14.2)
Recruitment Site	ResearchMatch	21 (14)
	MHAV	146 (67)
	Facebook	4 (3)
	Reddit	41 (27)
Number of Diverticulitis Episodes	1 - 5	172 (78.9)
	6 - 10	32 (14.7)
	11 - 20	10 (4.6)
	> 20	2 (0.9)






A



B



C

